Michael Share's research while affiliated with Multiple Myeloma - Institute for Myeloma & Bone Cancer Research and other places

What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.

It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.

If you're a ResearchGate member, you can follow this page to keep up with this author's work.

If you are this author, and you don't want us to display this page anymore, please let us know.

Publications (10)

Figure 1. PTN and M-CSF together induce VEC gene expression in fresh...
Figure 4. CD133 and CD45 expression in CD14 cells alone or treated with...
Figure 7. Microdissection of single cells lining blood vessels from...
Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: A novel mechanism of tumor-induced vasculogenesis
Article
Full-text available
  • Feb 2009
Enhanced angiogenesis is a hallmark of cancer. Pleiotrophin (PTN) is an angiogenic factor that is produced by many different human cancers and stimulates tumor blood vessel formation when it is expressed in malignant cancer cells. Recent studies show that monocytes may give rise to vascular endothelium. In these studies, we show that PTN combined w...
Cite
Download full-text
A Novel Targeted Therapeutic Approach to Multiple Myeloma Using Tumor Specific Anti-Sense RNA Sequences
Article
  • Nov 2008
Despite recent advances in the therapy of multiple myeloma (MM), the disease remains incurable. Current drugs for MM target not only MM but also normal cells. This limits the efficacy of these agents and may lead to significant morbidities for patients. Therefore, novel strategies are needed that allow targeting of tumor cells in these patients wit...
Cite
Request full-text
Zoledronic Acid Suppresses Vasculogenesis: A New Effect of Bisphosphonates.
Article
  • Nov 2007
Recent studies suggest that zoledronic acid (ZOL) and other nitrogen-containing bisphosphonates (BPs) inhibit angiogenesis by reducing angiogenic factor production and signaling by these factors. However, few studies have addressed the potential role of BPs in blocking the formation of new vasculature or so-called vasculogenesis. Thus, we determine...
Cite
Request full-text
Blockage of TRAF6 Signaling Inhibits Osteoclast Formation and Tumor Cell through Blocking the NF-kB and JNK Pathways in Multiple Myeloma.
Article
  • Nov 2007
We have recently shown that silencing of tumor necrosis factor receptor-associated factor 6 (TRAF6) with a C-terminal siRNA inhibits proliferation and increases apoptosis of multiple myeloma (MM) tumor cells. In addition, TRAF6 ubiquitin ligase is also essential for receptor activator of nuclear factor kappa B ligand (RANKL) signaling and osteoclas...
Cite
Request full-text
Cite
Request full-text
The mTOR Inhibitor RAD001 (Everolimus) Inhibits Myeloma Tumor Growth In Vivo and Enhances the Anti-MM Effects of Bortezomib and Arsenic Trioxide.
Article
  • Nov 2007
The mammalian target of rapamycin (mTOR) is an intracellular protein that acts as a central regulator of multiple signaling pathways (IGF, EGF, PDGF, VEGF, amino acids) that mediate abnormal growth, proliferation, survival and angiogenesis in cancer. mTOR is a critical component of the PI3K/Akt pathway, a key cell survival pathway that is dysregula...
Cite
Request full-text
The Combination of the mTOR Inhibitor Rapamycin and Protein Kinase C Inhibitors Produces Marked Synergistic Anti-Myeloma Effects.
Article
  • Nov 2007
Mammalian target of rapamycin (mTOR) is a central cell regulator involved in cell survival, growth and proliferation, and is being targeted for cancer therapy. There are two mTOR complexes, the rapamycin-sensitive mTORc1, and the rapamycin-insensitive mTORc2, both of which are downstream of the PI3K/Akt pathway. Protein Kinase C (PKC) refers to a f...
Cite
Request full-text
An Anti-VEGF Antibody, in Combination with Bortezomib, Markedly Inhibits Tumor Growth in SCID-hu Models of Human Multiple Myeloma.
Article
  • Nov 2007
Vascular endothelial growth factor (VEGF) is an important signaling protein that plays a critical role in vasculogenesis and angiogenesis, and serves as one of the contributors to physiological or pathological conditions that can stimulate the formation of new blood vessels. The uncontrolled growth of new blood vessels is an important contributor t...
Cite
Request full-text
The Novel Potent Pan-Deacetylase (DAC) Inhibitor, Panobinostat (LBH589), Markedly Enhances the Anti-Myeloma Effects of Chemotherapy In Vitro and In Vivo.
Article
  • Nov 2007
Deacetylase (DAC) inhibitors represent a new class of anti-cancer therapeutics that inhibit DAC enzymes and have been shown to have multiple effects in tumor cell lines including decreased oncoprotein expression (Bcr-Abl, HER-2), decreased angiogenesis, induction of apoptosis, induction of cell-cycle arrest, and decreased tumor cell motility and in...
Cite
Request full-text
Wnt/β-Catenin Signaling Is Essential for the Transdifferentiation of Monocytes into Endothelial Cells by mCSF and Pleiotrophin.
Article
  • Nov 2007
Angiogenesis is a hallmark of a variety of malignancies including multiple myeloma (MM). We have shown that MM patients express pleiotrophin (PTN), and this protein stimulates MM growth and prevents apoptosis. We have also demonstrated that PTN when combined with mCSF stimulates angiogenesis through the transdifferentiation (TD) of monocytes into e...
Cite
Request full-text

Citations

... In 69 cycles of treatment, there were seven grade 3–4 adverse events, including anaemia, infection, respiratory distress, hyperglycaemia, thrombocytopaenia and fatigue. Finally, combination therapy of HDAC inhibitors with standard chemotherapeutic agents such as liposomal doxorubicin and melphalan [64] as well as lenalidomide combination therapy also looks promising in the preclinical setting [65]. ...
Reference: HDAC inhibitor-based therapies and haematological malignancy
View
... VEGF clearly plays a critical role in the pathogenesis of solid tumors and myeloma (86), and preclinical studies of G6.31, a VEGF-directed murine-human monoclonal antibody, in combination with bortezomib, produced a marked increase in antimyeloma activity (87). The bevacizumab-bortezomib regimen is being evaluated in earlyphase glioma, renal cell cancer, NSCLC, and MM studies. ...
Reference: Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy
View
... Several studies have tested combinations of rapalogs with inhibitors of upstream targets, including PI. The postulation of synergism between PI3-K/Akt/mTOR pathway inhibition and bortezomib has been established both in in vitro and in in vivo studies involving non-Hodgkin lymphoma cells and xenograft models of MM [190,191]. In addition, since resistance to bortezomib-induced apoptosis has been demonstrated to be associated with Akt up-regulation, the combination of bortezomib with the alkylphospholipid perifosine (an oral bioactive signal transduction modulator with multiple effects, including Akt-inhibition) has been assessed in MM and prostate cancer cell lines [192][193][194]. ...
Reference: Drug Combinations with Proteasome Inhibitors in Antitumor Therapy
View
... We have recently demonstrated that MK is produced by human macrophages, monocyte-derived dendritic cells (MDDCs), and plasmacytoid dendritic cells (pDCs) upon stimulation through TLR4 [24]. In contrast, PTN production in human monocytes was not previously reported, and THP-1 does not have the capacity to produce PTN [29], although such production was detected in monocytic cells in quail [30]. However, PTN is produced by human tumor-associated macrophages [9]. ...
Reference: Differential Production of Midkine and Pleiotrophin by Innate APCs upon Stimulation through Nucleic Acid-Sensing TLRs
View full-text